Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. Danaher Corporation
  4. Financial Ratios
Danaher Corporation logo
Danaher Corporation DHR
$ 233.86 4.32%
report update icon

Quarterly report 2026-Q3
added 10-20-2026

Danaher Corporation Financial Ratios 2025-2006 | DHR

Brief overview of Danaher Corporation's financial ratios

Ratios are assessed across five available annual reports in the 2021–2025 interval.

Key multiples at the end of the period are P/E 41.37x (median 38.47x), EV/EBITDA 20.06x (median 20.06x), P/S 6.09x (median 6.8x). The multiple basket looks neutral against its history, differing from median levels by roughly 0%.

At the current P/E, inverse earnings yield is 2.4%, a useful bridge between price and business earnings.

Capital efficiency is characterized by ROE 6.9%, ROA 4.3%, ROCE 8.9%. Efficiency ratios are restrained, with capital and assets producing modest returns.

The cash cycle changed only slightly and ended at 77.5 days.

What the ratios show

Danaher Corporation's valuation and business quality look relatively balanced, with no pronounced distortion in either direction.

Annual Financial Ratios Danaher Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006

P/E

 41.4 39.0 38.5 25.1 30.5 42.4 40.2 28.8 28.4 21.8 13.7 16.9 14.7 13.2 12.4 9.6 11.8 12.6 5.6 -

P/S

 6.1 6.4 7.7 6.8 7.9 6.9 6.7 3.8 3.9 3.3 2.2 2.2 2.1 1.7 1.7 - - - - -

EPS

 5.1 5.3 6.4 9.8 8.8 5.0 4.1 3.8 3.6 3.7 4.8 3.7 3.9 3.5 3.2 2.7 1.8 2.1 4.4 -

EV (Enterprise Value)

 145 B 150 B 177 B 175 B 193 B 148 B 133 B 95.2 B 90.3 B 76.8 B 69.5 B 54.4 B 48.8 B 43.7 B 39.3 B 24.1 B 19.9 B 23.9 B 7.44 B -318 M

EBITDA per Share

 7.63 7.64 7.98 11.4 11.8 8.5 6.24 6.72 6.12 5.61 6.48 6.22 5.99 5.67 4.71 3.73 2.76 3.32 6.15 -

EV/EBITDA

 26.6 26.9 30.2 21.3 20.1 37.8 27.5 18.1 18.9 17.2 12.8 10.1 9.6 8.9 9.9 9.9 11.2 11.3 3.9 -

PEG

 209.84 5.21 5.59 1.7 1.75 6.12 4.6 5.16 -9.52 -0.93 0.46 -3.84 1.21 1.76 0.72 - - - - -

P/B

 1.8 2.0 2.2 2.1 2.4 2.0 4.0 2.7 2.7 2.4 1.9 1.9 1.8 1.7 1.6 1.3 1.2 1.7 - -

P/CF

 23.3 22.7 25.6 21.3 23.4 24.9 36.4 22.7 24.7 18.9 14.5 13.9 13.1 10.7 11.7 8.3 7.6 9.0 4.7 -

ROE %

 6.88 7.87 8.91 14.39 14.24 9.17 9.93 9.39 9.45 11.07 14.13 11.08 12.00 12.54 12.80 13.08 9.90 13.43 - -

ROA %

 4.33 5.03 5.64 8.55 7.73 4.79 4.85 5.54 5.34 5.64 6.96 7.02 7.77 7.26 7.25 8.07 5.88 7.53 - -

ROCE %

 8.93 9.82 9.73 15.04 14.12 10.64 5.72 7.92 7.22 7.16 8.25 10.86 10.86 10.77 9.89 14.95 12.38 18.22 - -

Current Ratio

 - - - - - - 5.2 1.5 1.4 1.0 1.3 1.7 2.0 1.8 1.5 2.6 2.5 2.3 - -

DSO

 55.3 57.0 61.3 59.8 63.8 59.3 65.0 64.0 70.1 68.9 70.4 66.6 65.9 65.3 69.2 - - - - -

DIO

 87.6 92.9 99.2 96.6 96.5 72.9 75.0 79.4 82.6 82.7 78.0 70.6 71.1 74.8 82.2 62.9 70.2 32.2 - -

DPO

 65.4 66.4 67.1 77.2 88.1 66.3 69.7 71.2 67.7 71.8 76.3 72.3 70.9 63.8 65.6 63.3 70.9 31.3 - -

Operating Cycle

 142.9 150.0 160.5 156.4 160.4 132.2 140.0 143.4 152.7 151.5 148.4 137.2 137.0 140.1 151.3 62.9 70.2 32.2 - -

Cash Conversion Cycle

 77.5 83.5 93.5 79.1 72.3 65.9 70.3 72.2 85.0 79.7 72.1 64.9 66.1 76.3 85.7 -0.4 -0.7 0.9 - -

All numbers in USD currency

Quarterly Financial Ratios Danaher Corporation

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q4 2010-Q3 2010-Q2 2010-Q1 2009-Q4 2009-Q3 2009-Q2

EPS

 1.28 0.77 1.33 1.87 1.13 1.23 1.47 - 1.27 1.25 1.47 2.09 2.13 2.28 2.35 - - 2.28 2.35 - 1.56 2.44 2.33 - 1.18 1.27 0.83 1.75 0.9 0.99 0.46 1.06 0.95 0.96 0.81 1.23 0.82 0.8 0.73 1.08 0.57 0.95 1.1 1 2.04 0.98 0.81 0.94 0.97 0.96 0.83 1.13 0.86 0.89 1 0.91 0.79 0.86 0.89 0.83 0.76 0.97 0.65 0.37 0.55 0.46 0.74 - 1.16 1.14

EBITDA per Share

 2.23 1.66 2.35 753 1.9 2.13 2.32 - 2.1 1.58 2.01 -239 3.26 3.55 3.57 - - 3.03 3.28 - 1.83 3.28 3.02 - 2.18 1.63 1.2 1.38 1.66 1.52 1.21 1.23 1.7 1.52 1.2 1.35 1.7 1.38 1.09 1.05 1.58 1.41 1.08 0.95 1.2 1.21 0.82 1.23 1.81 1.64 1.24 1.22 1.68 1.53 1.16 1.26 1.62 1.52 1.24 1.13 1.27 1.07 0.96 206 0.8 0.61 1.21 -40 1.78 1.6

ROE %

 8.32 8.14 8.90 9.06 7.60 8.15 8.36 6.33 10.06 11.20 12.62 14.22 14.10 14.52 13.62 9.99 9.99 14.17 14.33 10.61 12.83 12.49 9.82 6.05 10.20 10.18 10.27 9.87 8.37 8.52 8.49 9.40 10.00 9.82 9.54 9.45 9.45 8.98 9.72 11.10 10.76 14.98 15.06 14.17 14.10 11.08 11.04 11.11 11.81 11.57 11.43 12.04 11.83 12.05 12.45 12.58 12.64 12.85 13.53 12.85 11.52 11.44 10.15 9.65 11.26 12.03 13.19 3.65 3.79 3.71

ROA %

 5.18 5.15 5.65 5.91 4.96 5.22 6.07 4.67 6.51 7.14 5.83 7.83 7.85 8.08 7.52 5.53 5.53 7.81 7.81 5.74 6.90 6.71 5.20 3.16 5.18 5.10 5.06 4.81 4.35 4.66 4.90 5.54 5.82 5.66 5.44 5.34 5.16 4.79 5.05 5.64 5.42 7.46 7.46 6.96 7.32 6.25 6.64 7.02 7.51 7.39 7.34 7.77 7.41 7.35 7.40 7.26 7.25 7.34 7.68 7.25 6.71 6.75 6.10 5.87 6.56 6.90 7.46 2.05 2.13 2.08

ROCE %

 9.51 9.12 10.01 9.96 8.92 9.30 9.42 6.96 11.24 13.27 15.75 17.98 18.44 18.83 17.12 12.43 12.43 17.12 16.81 12.12 14.86 13.97 11.04 6.61 9.79 9.62 10.18 10.80 10.68 10.76 10.77 10.83 11.32 11.56 11.44 11.35 10.96 11.11 11.63 11.96 11.54 10.53 9.90 9.13 10.08 11.76 13.05 14.32 14.43 14.22 14.07 13.94 14.66 15.13 15.80 16.64 16.71 16.54 15.89 15.48 13.80 13.99 13.34 12.80 12.88 14.21 16.46 3.01 5.32 5.20

Current Ratio

 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 2.3 - - - - - -

DSO

 59.0 60.1 59.2 49.2 55.7 56.2 58.7 - 63.6 30.3 32.3 63.1 58.6 57.9 29.2 - - 52.6 53.6 - 52.4 55.2 57.7 - 62.7 69.7 76.0 59.8 66.5 65.5 67.3 55.5 65.6 63.9 68.1 63.2 71.0 71.2 72.8 63.4 70.4 68.5 71.8 63.0 90.3 72.9 72.0 60.2 68.6 66.8 67.8 61.0 67.5 66.5 69.0 59.9 67.5 65.5 66.8 59.0 62.6 76.5 68.8 - - - - - - -

DIO

 89.8 94.1 98.6 75.0 88.7 91.8 97.3 - 100.8 45.6 54.6 569.1 92.2 93.7 47.6 - - 95.3 89.3 - - 44.8 88.6 - - - 39.1 - - - 39.9 - - - 40.9 - 84.4 80.0 84.7 - 84.5 83.8 85.2 - 103.4 82.5 79.5 - 73.1 71.3 73.6 - 72.5 72.6 77.5 - 77.4 75.3 78.8 - 71.8 94.6 82.0 35.6 63.4 64.2 71.2 109.4 61.4 -

DPO

 66.5 69.7 73.6 56.4 66.7 69.1 69.5 - 68.6 31.1 36.7 402.2 68.0 69.2 35.1 - - 71.9 75.3 - 65.2 73.4 80.9 - 70.3 76.5 85.6 - 71.4 70.5 73.6 - 72.3 72.2 71.7 - 69.2 67.9 73.0 - 73.4 72.8 74.7 - 97.0 80.7 79.4 - 74.9 73.0 74.6 - 72.3 72.4 71.6 - 66.0 64.2 65.1 - 57.4 75.5 73.1 37.7 67.1 68.0 72.0 106.2 - -

Operating Cycle

 - 154.3 157.8 124.2 144.4 148.0 155.4 - 164.4 75.9 - 632.2 150.7 151.6 76.8 - - 147.9 142.9 - 52.4 100.0 146.3 - 62.7 69.7 115.1 59.8 66.5 65.5 107.2 55.5 65.6 63.9 109.1 63.2 155.4 151.3 157.5 63.4 154.8 152.4 157.0 63.0 193.7 155.5 151.5 60.2 141.8 138.1 141.4 61.0 140.0 139.1 146.4 59.9 144.9 140.8 145.6 59.0 134.4 171.1 - 35.6 63.4 64.2 71.2 109.4 61.4 -

Cash Conversion Cycle

 - 84.5 84.2 67.8 77.6 78.9 84.3 - 95.8 44.8 - 230.0 82.7 82.4 41.6 - - 76.0 67.6 - -12.8 26.6 65.5 - -7.6 -6.8 29.5 59.8 -4.8 -5.0 33.5 55.5 -6.7 -8.3 37.4 63.2 86.2 83.3 84.5 63.4 81.5 79.5 82.3 63.0 96.7 74.8 72.1 60.2 66.9 65.1 66.8 61.0 67.7 66.7 74.8 59.9 78.9 76.6 80.5 59.0 77.1 95.6 - -2.1 -3.7 -3.8 -0.8 3.2 61.4 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Danaher Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
 		- -8.98 % $ 14.8 K usaUSA
Biomerica Biomerica
BMRA
 		$ 1.71 -0.51 % $ 4.98 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
 		$ 5.57 0.54 % $ 516 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
 		$ 2.14 9.18 % $ 642 M usaUSA
Neuronetics Neuronetics
STIM
 		$ 2.01 1.52 % $ 133 M usaUSA
Agilent Technologies Agilent Technologies
A
 		$ 177.75 2.74 % $ 50.5 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
 		$ 344.87 9.31 % $ 17.1 B usaUSA
Biodesix Biodesix
BDSX
 		$ 23.93 0.25 % $ 181 M usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
 		$ 13.51 6.71 % $ 142 M chinaChina
Bioventus Bioventus
BVS
 		$ 14.24 2.08 % $ 949 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
 		- 0.22 % $ 16.8 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
 		$ 70.74 2.23 % $ 3.77 B usaUSA
DermTech DermTech
DMTK
 		- -11.32 % $ 2.94 M usaUSA
Co-Diagnostics Co-Diagnostics
CODX
 		$ 0.64 -0.82 % $ 851 K usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
 		$ 20.13 -0.98 % $ 620 M usaUSA
Surmodics Surmodics
SRDX
 		- - $ 608 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
 		$ 276.63 3.28 % $ 47.6 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
 		- - $ 21.2 M usaUSA
Syneos Health Syneos Health
SYNH
 		- - $ 4.46 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
 		- -34.28 % $ 263 K israelIsrael
Renalytix AI plc Renalytix AI plc
RNLX
 		- 5.66 % $ 22.7 M britainBritain
Psychemedics Corporation Psychemedics Corporation
PMD
 		- -1.84 % $ 15.3 M usaUSA
T2 Biosystems T2 Biosystems
TTOO
 		- -39.35 % $ 313 K usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
 		- - $ 1.49 B usaUSA
Akumin Akumin
AKU
 		- -17.87 % $ 25.9 M canadaCanada
Accelerate Diagnostics Accelerate Diagnostics
AXDX
 		- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
 		- -13.05 % $ 7.29 M usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
 		$ 323.75 0.19 % $ 26.9 B usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
 		$ 2.71 1.12 % $ 88 K usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
 		$ 100.24 -0.15 % $ 6.77 B usaUSA
Heska Corporation Heska Corporation
HSKA
 		- - $ 1.31 B usaUSA
Celcuity Celcuity
CELC
 		$ 61.56 2.6 % $ 2.88 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
 		- -20.0 % $ 1.06 M usaUSA
Medpace Holdings Medpace Holdings
MEDP
 		$ 662.48 6.43 % $ 19.1 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
 		$ 1 677.94 2.69 % $ 34.6 B schweizSchweiz
NeoGenomics NeoGenomics
NEO
 		$ 17.04 2.53 % $ 2.18 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
 		$ 11.79 0.6 % $ 2.56 B usaUSA
National Research Corporation National Research Corporation
NRC
 		$ 20.31 -1.84 % $ 455 M usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
 		$ 11.98 -0.42 % $ 407 M israelIsrael
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
 		$ 26.23 0.85 % $ 24.9 B niderlandNiderland
Precipio Precipio
PRPO
 		$ 21.25 -2.16 % $ 34.1 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
 		$ 34.37 3.68 % $ 996 M usaUSA
Guardant Health Guardant Health
GH
 		$ 166.66 2.5 % $ 20.9 B usaUSA
RadNet RadNet
RDNT
 		$ 68.41 -1.78 % $ 5.14 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
 		$ 3.68 -9.8 % $ 14.7 M israelIsrael
DexCom DexCom
DXCM
 		$ 80.26 -6.39 % $ 31.3 B usaUSA
Senseonics Holdings Senseonics Holdings
SENS
 		$ 7.97 -2.92 % $ 333 M usaUSA
Illumina Illumina
ILMN
 		$ 282.86 5.57 % $ 43.8 B usaUSA
Quotient Limited Quotient Limited
QTNT
 		- -11.32 % $ 1.1 M schweizSchweiz